DE60035191D1 - Materialien und methoden zur entwicklung von dopaminergen neuronen - Google Patents

Materialien und methoden zur entwicklung von dopaminergen neuronen

Info

Publication number
DE60035191D1
DE60035191D1 DE60035191T DE60035191T DE60035191D1 DE 60035191 D1 DE60035191 D1 DE 60035191D1 DE 60035191 T DE60035191 T DE 60035191T DE 60035191 T DE60035191 T DE 60035191T DE 60035191 D1 DE60035191 D1 DE 60035191D1
Authority
DE
Germany
Prior art keywords
cells
neural
nurr1
neural stem
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60035191T
Other languages
English (en)
Other versions
DE60035191T2 (de
Inventor
Ernest Arenas
Thomas Perlmann
Evan Y Snyder
Joseph Wagner
Peter Akerud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuroTherapeutics AB
Original Assignee
NeuroTherapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuroTherapeutics AB filed Critical NeuroTherapeutics AB
Application granted granted Critical
Publication of DE60035191D1 publication Critical patent/DE60035191D1/de
Publication of DE60035191T2 publication Critical patent/DE60035191T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
DE60035191T 1999-05-03 2000-04-27 Materialien und methoden zur entwicklung von dopaminergen neuronen Expired - Fee Related DE60035191T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13231799P 1999-05-03 1999-05-03
US132317P 1999-05-03
PCT/EP2000/003842 WO2000066713A2 (en) 1999-05-03 2000-04-27 Materials and methods relating to neuronal development

Publications (2)

Publication Number Publication Date
DE60035191D1 true DE60035191D1 (de) 2007-07-26
DE60035191T2 DE60035191T2 (de) 2008-06-19

Family

ID=22453462

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035191T Expired - Fee Related DE60035191T2 (de) 1999-05-03 2000-04-27 Materialien und methoden zur entwicklung von dopaminergen neuronen

Country Status (10)

Country Link
US (1) US7465582B1 (de)
EP (1) EP1173548B1 (de)
JP (1) JP2002542818A (de)
AT (1) ATE364688T1 (de)
AU (1) AU4752700A (de)
CA (1) CA2371260A1 (de)
DE (1) DE60035191T2 (de)
DK (1) DK1173548T3 (de)
ES (1) ES2290032T3 (de)
WO (1) WO2000066713A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129034B2 (en) 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
WO2003037260A2 (en) * 2001-10-30 2003-05-08 Biogen, Inc. Methods and compositions for treating parkinson's disease
EP2360241A1 (de) 2002-06-05 2011-08-24 ES Cell International Pte Ltd. Stammzellen
AU2003269354B2 (en) * 2002-09-24 2008-03-06 Neuro Therapeutics Ab Methods for promoting dopaminergic neuronal development by using NG4A-subfamily and Wnt-ligands
KR20040079669A (ko) * 2003-03-10 2004-09-16 학교법인 한양학원 Ｎｕｒｒ1 과발현에 의한 도파민성 신경세포의 분화방법
US8426200B2 (en) 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
EP1779867A4 (de) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd Mittel zur förderung der nervenreveneration
WO2007119180A2 (en) * 2006-04-07 2007-10-25 Neuro Therapeutics Ab Survival and development of neural cells
EP1897937A1 (de) * 2006-09-07 2008-03-12 NeuroProgen GmbH Leipzig Verfahren zur Züchtung von neuralen Vorläuferzellen
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8097256B2 (en) 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
ES2565779T3 (es) 2008-09-02 2016-04-06 Cedars-Sinai Medical Center Epítopos CD133
KR101181423B1 (ko) * 2009-01-30 2012-09-19 한양대학교 산학협력단 Ｎｕｒｒ1 변이체 발현을 이용한 개선된 도파민 신경세포의유도방법
WO2010129895A2 (en) 2009-05-07 2010-11-11 Immunocellular Therapeutics, Ltd. Cd133 epitopes
KR101358601B1 (ko) 2011-12-30 2014-02-05 한양대학교 산학협력단 도파민 뉴런의 제조 방법
EP2956544B1 (de) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Krebsimpfstoffe und impfverfahren
JP6340216B2 (ja) 2014-03-07 2018-06-06 株式会社日立ハイテクノロジーズ 走査電子顕微鏡
KR102203034B1 (ko) * 2017-11-06 2021-01-14 한양대학교 산학협력단 중뇌 유래의 성상교세포와 도파민 신경줄기세포의 공동 이식에 의한 도파민 신경세포의 이식 치료 효과 개선
JP2019106895A (ja) * 2017-12-15 2019-07-04 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ 神経幹細胞または神経前駆細胞からドーパミン神経細胞への分化方法
CN111484977B (zh) * 2019-01-25 2023-05-16 中国科学院脑科学与智能技术卓越创新中心 重编程产生功能性去甲肾上腺素能神经元的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
CA2200709A1 (en) 1994-09-23 1996-03-28 Samuel Weis In vitro models of cns function and dysfunction
US6284539B1 (en) * 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6312949B1 (en) 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
WO2001088104A2 (en) 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations
US20020114788A1 (en) 2000-07-27 2002-08-22 Ole Isacson Cell implantation therapy for neurological diseases or disorders

Also Published As

Publication number Publication date
DE60035191T2 (de) 2008-06-19
WO2000066713A2 (en) 2000-11-09
ES2290032T3 (es) 2008-02-16
AU4752700A (en) 2000-11-17
EP1173548A2 (de) 2002-01-23
ATE364688T1 (de) 2007-07-15
EP1173548B1 (de) 2007-06-13
WO2000066713A3 (en) 2001-04-05
JP2002542818A (ja) 2002-12-17
CA2371260A1 (en) 2000-11-09
DK1173548T3 (da) 2007-10-08
US7465582B1 (en) 2008-12-16

Similar Documents

Publication Publication Date Title
DE60035191D1 (de) Materialien und methoden zur entwicklung von dopaminergen neuronen
Tepper et al. Heterogeneity and diversity of striatal GABAergic interneurons: update 2018
Veena et al. Exposure to enriched environment restores the survival and differentiation of new born cells in the hippocampus and ameliorates depressive symptoms in chronically stressed rats
Bekoff et al. Physiological properties of dissociated muscle fibres obtained from innervated and denervated adult rat muscle.
Marinelli et al. Heterogeneity of dopamine neuron activity across traits and states
Brandt et al. Physical exercise increases Notch activity, proliferation and cell cycle exit of type‐3 progenitor cells in adult hippocampal neurogenesis
Bertilsson et al. Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease
Hitoshi et al. Antidepressant drugs reverse the loss of adult neural stem cells following chronic stress
Huntley et al. Temporal sequence of neurotransmitter expression by developing neurons of fetal monkey visual cortex
Garcia-Segura Hormones and brain plasticity
Hutchison et al. Sexual dimorphism in the developmental regulation of brain aromatase
WO2001088104A3 (en) Neural progenitor cell populations
Nakagawa et al. Diversity of thalamic progenitor cells and postmitotic neurons
JP2002542818A5 (de)
He et al. MicroRNA expression profiles of neural stem cells following valproate inducement
Sato et al. Hormone-secreting and hormone-responsive cell cultures
Coronel-Cruz et al. Connexin 30.2 is expressed in mouse pancreatic beta cells
Jhaveri et al. Activation of different neural precursor populations in the adult hippocampus: does this lead to new neurons with discrete functions?
Rohrbacher et al. Electrophysiological characteristics of substantia nigra neurons in organotypic cultures: spontaneous and evoked activities
Bohl et al. Directed evolution of motor neurons from genetically engineered neural precursors
Aizawa et al. Electrically stimulated modulation of cellular function in proliferation, differentiation, and gene expression
Puglisi-Allegra et al. Circadian variations in stress-induced analgesia
Huang et al. Tlx3 controls cholinergic transmitter and Peptide phenotypes in a subset of prenatal sympathetic neurons
Nakamichi et al. Group III metabotropic glutamate receptor activation suppresses self‐replication of undifferentiated neocortical progenitor cells
Barrera et al. Galanin‐mediated anxiolytic effect in rat central amygdala is not a result of corelease from noradrenergic terminals

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee